Trulieve Cannabis Corp. annual report, FY2023

Trulieve Cannabis Corp. — FY2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report; most operating comparisons are full-year versus full-year.

Business context

Trulieve is a vertically integrated U.S. cannabis operator with licenses in nine states. At year-end it reported 192 dispensaries and 16 cultivation and processing facilities, concentrated in Florida, Arizona, and Pennsylvania. The company describes Florida, Pennsylvania, and Arizona as the anchors of its regional hubs. It exited Massachusetts operations during 2023 and had previously discontinued Nevada operations.

Financial performance and liquidity

MetricFY2023FY2022
Revenue$1.129 billion$1.218 billion
Gross profit / margin$588.6 million / 52.1%$689.1 million / 56.6%
Operating income (loss)$(221.6) million$50.2 million
Net loss from continuing operations$(435.9) million$(182.6) million
Net loss attributable to common shareholders, including discontinued operations$(526.8) million$(246.1) million
Adjusted EBITDA (non-GAAP)$322.3 million$398.2 million
Cash provided by operating activities$201.8 million$23.1 million

Revenue fell 7.3%, including a $74.9 million reduction in retail revenue and an $11.7 million reduction in wholesale revenue. Management cited competition, increased promotions, underperforming retail asset exits, and a shift toward higher-margin retail over wholesale. Gross margin declined amid price compression, promotional activity, a customer shift toward value-tier products, inventory-reduction efforts, and costs from excess or ramping capacity.

FY2023 operating loss included a $307.6 million goodwill impairment recorded in the second quarter. Adjusted EBITDA, a non-GAAP measure, declined 19%; management attributed the decrease mainly to competition and margin pressure, partly offset by payroll efficiencies and streamlining. The company also recorded $97.2 million of discontinued-operations losses.

Year-end cash and cash equivalents were $201.4 million, versus $207.2 million a year earlier; restricted cash was $6.6 million. Operating cash flow improved substantially, helped by inventory reductions and lower selling and administrative costs, while cash flow included continuing and discontinued operations. Investing activities used $37.5 million and financing activities used $175.6 million; cash, cash equivalents, and restricted cash decreased by $11.2 million.

At year-end, private placement notes had $368.0 million of principal outstanding and notes payable totaled $121.8 million. The balance sheet also included $100.0 million of finance lease liabilities and $138.1 million of construction finance liabilities, alongside operating leases. Reported contractual obligations totaled $1.194 billion, including leases and construction finance liabilities. In 2023, Trulieve repurchased $57.0 million principal of 2026 notes at a discount and redeemed $130.0 million principal of 2024 notes; it reported expected net interest savings of approximately $10.0 million. Management said existing cash should cover anticipated needs for at least 12 months from the filing date.

Material changes, outlook, and risks

  • Taxes: The company disputes tax liability associated with IRC Section 280E and reported $180.4 million in uncertain tax position liabilities at year-end, including $152.1 million related to its 280E position. It received $50.3 million in tax refunds in January 2024; the filing says this increases unrecognized tax benefits. The FY2023 tax provision was $151.4 million despite a pretax loss.
  • Debt actions: The 2023 note repurchases and early redemption reduced outstanding private placement note principal from $555.0 million to $368.0 million. The company also entered into a $25.0 million mortgage note at 8.31%.
  • Strategic exits and impairment: Massachusetts and Nevada are presented as discontinued operations. The company recorded $69.5 million of discontinued-operations impairment and disposal losses in 2023, in addition to the goodwill impairment in continuing operations.
  • Guidance: The filing provides no specific revenue, earnings, or cash-flow forecast. Management expects continued investment and costs for operations, growth, and regulatory compliance, and states that cash is sufficient for at least 12 months.
  • Key risks: Cannabis remains illegal under U.S. federal law; rescheduling to Schedule III was under DEA review at the filing date and was not assured. The company also cites Section 280E tax exposure, regulatory and licensing uncertainty, limited banking access, competition and price pressure, significant debt and covenant obligations, and concentration in Florida and other core markets.
  • Financial reporting controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023. The auditor issued an adverse opinion on internal control, citing weaknesses in IT general controls and management review controls over inventory valuation. The auditor nevertheless issued an unqualified opinion on the financial statements.
  • Leadership: Wes Getman became CFO on January 1, 2024, and Marie Zhang became COO on January 29, 2024.

Important facts for investors to verify

  • Whether the 280E tax position and related refunds withstand IRS review, and how the $180.4 million uncertain tax liability may change.
  • Whether inventory valuation and IT-control remediation is completed, tested, and sustained; the filing identifies inventory valuation as a critical audit matter.
  • Debt maturities, covenant compliance, refinancing capacity, and the cash impact of lease and construction finance obligations.
  • Whether revenue and margins stabilize amid competition, discounting, product-mix changes, and the cost of underused or ramping facilities.
  • Progress and remaining liabilities from market exits, including discontinued operations and assets held for sale.
  • Actual regulatory developments, including federal rescheduling and the potential Florida adult-use ballot measure; neither outcome is assured in the filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.